Genmab has been granted a patent for novel heterodimeric antibody-Fc-containing proteins, including bispecific antibodies, and innovative methods for their production. The patent claims a heterodimeric antibody with specific characteristics in the Fc region, offering potential advancements in therapeutic antibody development. GlobalData’s report on Genmab gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Genmab AS - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Genmab, Personalized cancer vaccines was a key innovation area identified from patents. Genmab's grant share as of January 2024 was 37%. Grant share is based on the ratio of number of grants to total number of patents.

Patent granted for novel bispecific antibodies production methods

Source: United States Patent and Trademark Office (USPTO). Credit: Genmab AS

A recently granted patent (Publication Number: US11866514B2) discloses a novel heterodimeric antibody design. The patent claims a heterodimeric antibody comprising two heavy chains, with each chain having a different Fc region derived from human IgG4. The second Fc region includes specific amino acid substitutions at positions 405 and 409, distinct from the first Fc region. Additionally, both heavy chains contain a Cys-Pro-Pro-Cys sequence in the hinge region. The antibody further includes two full-length light chains and is of the human IgG4 isotype, except for the specified substitutions and hinge region. Notably, the first and second heavy chains bind different epitopes, enhancing the antibody's potential applications in targeted therapy.

Moreover, the patent covers the pharmaceutical compositions containing the heterodimeric antibody, emphasizing its therapeutic utility. The patent also details a method for obtaining the heterodimeric antibody, involving the co-expression of nucleic acid constructs in a host cell and subsequent isolation of the antibody from the cell culture. The method allows for the production of the antibody with specific characteristics, such as the presence of two full-length light chains and the unique amino acid substitutions in the Fc regions. The patent further extends to pharmaceutical compositions comprising the heterodimeric antibody and a pharmaceutically-acceptable carrier, highlighting the potential for developing novel therapeutic interventions based on this innovative antibody design.

To know more about GlobalData’s detailed insights on Genmab, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies